In contrast, the remaining two approved CAR-T-cells, ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), have been approved for refractory multiple myelomas since they target the B-Cell Maturation Antigen (BCMA), also known as Tumor Necrosis Factor Receptor Superfamily member 17 (TNFRSF17), which is expressed in mature B-cells and overactivated in this hematological neoplasm [8]. This evidence concerns the gene TNFRSF17 and hematopoietic and lymphoid system neoplasm.